News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Deals
Symrise S.R.L. Buys 20 Percent in U.S. Biotech Company, Therapeutic Peptides Inc.
August 19, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
HOLZMINDEN, Germany (Thomson Financial) - German scents and flavours maker Symrise AG. said it acquired a 20 percent stake in Therapeutic Peptides Inc., winning distribution rights to the U.S. biotechnology company's ingredients for cosmetics.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
MORE ON THIS TOPIC
IN PARTNERSHIP WITH IQVIA
AI Is Taking Over Drug Safety Monitoring–But There’s One Thing It Can’t Replace
July 17, 2025
·
1 min read
·
Lori Ellis
Mergers & acquisitions
Merck, AstraZeneca Cancer Collaborator Gets Swallowed Up by Sino Biopharm
July 16, 2025
·
1 min read
·
Tristan Manalac
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
·
1 min read
·
Dan Samorodnitsky
Gene therapy
AstraZeneca Gains More Gene Therapy AAVs in JCR Deal Worth up to $825M
July 9, 2025
·
1 min read
·
Dan Samorodnitsky